SMi�s Ophthalmic Drugs: Queen’s University Belfast and Santen to Present Opening Keynote

London, United Kingdom, November 08, 2018 –(PR.com)– Day 1 – Opening Keynote Address: New Strategies for Treating Retinal Vascular Diseases

Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments.*

Discover advancements in the treatment of ocular diseases as Professor Alan Stitt, Dean of Innovation and Impact, Queen’s University Belfast presents an overview of pathogenesis of ischaemic retinopathies, a disease that affects the immature retinal vascular system, as well as the cellular and molecular mechanisms of the disease.

Day 2 – Opening Keynote Address: Glaucoma / retinal protection treatments

Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterised by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in glaucoma remains incompletely understood and a broad range of possible mechanisms have been implicated.*

Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen, USA will present the latest developments in the treatment of glaucoma, which will explore the novel and recently approved drugs in view, new devices to lower and control IOP and a case for pathways to retinoprotection.

SMi Presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com

Sponsors: AERO PUMP | Experimentica | Nemera | Ora Europe Ltd
Sources: https://bit.ly/2BVa7lS | https://go.nature.com/2PEYouy